Hot Products

Astragaloside I
Catalog No: CFN99172

Astragaloside Ι may protect the cerebral tissue against the free radical damage in ischemia and inhibit the activation of BV-2 cells induced by LPS through suppressing the activation of PI3K/Akt/NF-κB pathway. It stimulates osteoblast differentiation through the Wnt/β-catenin signaling pathway, which also activates the BMP pathway and RANK pathway.

Astragaloside II
Catalog No: CFN99173

Astragaloside II is a potent autophagy inhibitor and multidrug resistance (MDR) reversal agent, which restores chemosensitivity of anticancer agent cisplatin and enhances tumor cell death. It has immunomodulating activity, can trigger T cell activation through regulation of CD45 protein tyrosine phosphatase activity, it induces osteogenic activities of osteoblasts through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways.

Astragaloside III
Catalog No: CFN99174

Astragaloside III has anti-gastric ulcer effects, and exhibits strong growth-promoting effects in cultured GES-1 cells. Astragaloside III can effectively reduce cancer cell survival in vitro and inhibit the tumor growth in vivo, the potential mechanism is the induction of cell apoptosis signaling pathways, suggests that it provides a new therapeutic tool to treat breast cancer.

Astragaloside IV
Catalog No: CFN99171

Astragaloside IV can protect the myocardium against ischemia/reperfusion injury, inhibit adenovirus replication and apoptosis in A549 cells in vitro, has anti-fibrotic effect against systemic sclerosis, and may be useful in ameliorating food-induced metabolic syndrome and membranous nephropathy. It suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.

Astragenol
Catalog No: CFN91686

Astragenol is an intermediate used for Astragenol derivative synthesis. Astragenol derivatives are promising anti-inflammatory agents for prostate cancer research.

Astrasieversianin VII
Catalog No: CFN90648

Isoastragaloside II is an astragaloside, which is isolated from the hairy root culture of Astragalus membranaceus.

Astringin
Catalog No: CFN92486

Astringinin is a potent antiarrhythmic agent with cardioprotective activity in ischemic and ischemic-reperfused rat heart, the beneficial effects of astringinin in the ischemic and ischemic-reperfused hearts may be correlated with its antioxidant activity and upregulation of NO production. Astringinin can significantly attenuate proinflammatory responses and hepatic injury after trauma-hemorrhage, the salutary effects of astringinin administration on attenuation of hepatic injury following trauma-hemorrhage are likely due to reduction of pro-inflammatory mediator levels.

Atalantoflavone
Catalog No: CFN97991

Atalantoflavone shows urease inhibitory potential. It displays weak cytotoxic activity against the human Caucasian prostate adenocarcinoma cell line PC-3.

Atherosperminine
Catalog No: CFN91008

Atherosperminine shows cholinesterase inhibitory activity against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Atherosperminine shows strong anti-plasmodial activity against Plasmodium falciparum, with the IC50 value of 5.80 uM, it also shows antioxidant activity in a DPPH assay with the IC50 value of 54.53 ug/mL. Atherosperminine exerts a non-specific relaxant effect on the trachealis, its major mechanism of action appears to be inhibition of cAMP phosphodiesterase.

Atractylenolide I
Catalog No: CFN99944

Atractylenolide I, a TLR4-antagonizing agent, shows a wide spectrum of pharmacological activities such as anti-inflammatory, digestion promoting,significant antitumor, and antioxidant effects. It ameliorates sepsis syndrome,liver and kidney functions by reduction of pro-inflammatory cytokines and LPS.